

## AMENDMENTS TO THE CLAIMS

**This listing of claims will replace all prior versions and listings of claims in the application:**

### **LISTING OF CLAIMS:**

1. (currently amended): An ~~oncogene~~ isolated polynucleotide ~~derived from human involving development of cervical cancer~~, comprising a nucleotide sequence encoding the polypeptide represented by an amino acid sequence of SEQ. ID. No.1.
2. (currently amended): The polynucleotide ~~of as claimed in Claim 1 wherein~~ comprising the nucleotide sequence set forth in ~~encoding the amino acid sequence of SEQ. ID. No.1 is a nucleotide sequence of SEQ. ID. No.2.~~
3. (currently amended): A recombinant polypeptide or its salts, comprising ~~an~~ the amino acid sequence of SEQ. ID. No.1 ~~or a partial amino acid sequence of the amino acid sequence.~~
4. (original): A recombinant oncogenic protein comprising an amino acid sequence of SEQ. ID. No.1.
5. (currently amended): A recombinant vector comprising a polynucleotide ~~encoding the recombinant peptide as claimed in Claim 3~~ of Claim 1 or Claim 2.
6. (canceled): A recombinant vector comprising the polynucleotide as claimed in Claim 1 or 2.
7. (currently amended): A transformed cell produced by transforming a host cell ~~using~~ with the recombinant vector as claimed in of Claim 5.

8. (canceled): A transformed cell produced by transforming a host cell using the recombinant vector as claimed in Claim 6.

9. (currently amended): A process for producing the recombinant polypeptide as ~~claimed in~~ of Claim 3 or its salts comprising the steps of:

transforming a host cell with a recombinant vector comprising a polynucleotide encoding the polypeptide represented by SEQ. ID. No. 1, thereby creating a transformed cell;

culturing the transformed cell as claimed in Claim 7 to allow whereby the transformed cell to produce the said recombinant polypeptide as claimed in Claim 3; and

collecting the said recombinant polypeptide produced from the culture.

10. (currently amended): A process for producing the recombinant oncogenic protein ~~of as claimed in~~ Claim 4 comprising the steps of:

transforming a host cell with a recombinant vector comprising a polynucleotide encoding an oncogenic protein with the amino acid sequence of SEQ. ID. No. 1, thereby creating a transformed cell;

culturing the transformed cell as claimed in Claim 8 to allow whereby the transformed cell to produce the said recombinant oncogenic protein as claimed in Claim 4; and

collecting the said recombinant oncogenic protein produced from the culture.

11. (currently amended): An antibody ~~which is a specific antibody~~ generated using the recombinant polypeptide of ~~as claimed in~~ Claim 3 as an immunogen.

12. (currently amended): The antibody ~~as claimed in~~ of Claim 11, wherein ~~the said~~ antibody is reactive to an epitope of said recombinant polypeptide, and wherein said epitope is

~~within partial amino acids sequence of 623 to 1185 of said recombinant polypeptide region of the amino acid sequence of SEQ. ID. No.1.~~

13. (currently amended): ~~An antibody reagent kit for an antigen-antibody reaction comprising the antibody as claimed in of Claim 11, wherein said antibody detects available for detecting an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1 or a peptide fragment derived from the oncogenic protein.~~

14. (currently amended): ~~A diagnosis The kit being usable of claim 13 for detection of an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1 or a peptide fragment derived from said the oncogenic protein, wherein said peptide fragment contains the epitope recognized by said antibody by means of an antigen-antibody reaction, comprising the antibody as claimed in Claim 11.~~

15. (currently amended): ~~An antisense polynucleotide comprising a complementary nucleotide sequence to a partial nucleotide sequence complementary to of the a nucleotide sequence of SEQ. ID. No.2, wherein which is a DNA fragment- said polynucleotide having has at least a length selected from the region of 15 to 300 bases.~~

16. (currently amended): ~~A probe hybridization kit available for detecting an mRNA comprising the nucleotide sequence of SEQ. ID. No.2, its partial nucleotide sequence or cDNA prepared by the mRNA, comprising the antisense polynucleotide as claimed in of Claim 15 as the DNA probe therein.~~

17. (currently amended): ~~A diagnosis kit available for detecting expression of mRNA comprising the nucleotide sequence of SEQ. ID. No.2, which is translated into an oncogenic~~

protein comprising the amino acid sequence of SEQ. ID. No.1, ~~by means of a probe hybridization method, comprising the antisense polynucleotide of as claimed in Claim 15 as the hybridization probe.~~

18. (currently amended): A primer pair for PCR amplification of cDNA comprising the nucleotide sequence of SEQ. ID. No.2, consisting of the following paired primers of:

a nucleotide sequence :

5'-TTGGATCCATGACATCCAGATTTGGGAAAACATACAGTAGG-3'; and

a nucleotide sequence :

5'-TTGAATTCCTAGCAATGTTCCAAATATTCAATCACTCTAGA-3'.

19. (currently amended): A primer pair for PCR amplification of a partial chain in cDNA comprising a nucleotide sequence of SEQ. ID. No.2, consisting of the following paired primers of:

5'-GAATTCATAGGCACAGCGCTGAACTGTGTG-3'; and

5'-TTGAATTCCTAGCAATGTTCCAAATATTCA-3'.

20. (currently amended): A double strand of short-chain interfering RNA (siRNA) capable of inhibiting expression of a target mRNA comprising the nucleotide sequence of SEQ. ID. No. 2 in a cervical cancer cell, wherein the siRNA has a nucleotide sequence:  
CGGACTACCCTTAGCACAA.

21. (currently amended): A pharmaceutical composition for inhibiting expression of a target mRNA comprising the nucleotide sequence of SEQ. ID. No.2 in a cervical cancer cell to

SAITO et al.  
Q79447  
Preliminary Amendment

arrest growth of said the carcinoma cell, comprising the siRNA ~~double strand of short chain~~  
~~interfering RNA as claimed in~~ of Claim 20.